Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on May 05, 2023 2:51pm
157 Views
Post# 35433602

RE:RE:Eternal Groundhog Day

RE:RE:Eternal Groundhog DayAs a sidenote, GUD has been buying back shares aggressively and are on pace to maxing out the allotted 8M shares until mid July which would put us at around 107M shares outstanding. 34M of them owned by goodman and Armoyan alone.

One last note on change. The company has now put potential exit dates on the fund investments. Large chunks aiming for 2025-2027 and all by 2030. For those who are patient (maybe extremely patient) what will the company look like then? 

I think they will have moved into another geographic area by then and likely bolstered their Latam (mexico) region while growing exisitng platform. I would think the market would much prefer a pure play pharma company. What will our shares oustanding be by then? 

So where could that leave us? I think it could be multiples higher than 5$/share
<< Previous
Bullboard Posts
Next >>